Clinical evaluation of the new tumor marker TAG-72

F. Guadagni, M. Roselli, P. Ferroni, T. Amato, D. Colcher, J. W. Greiner, J. Schlom

Research output: Contribution to journalArticle

Abstract

Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight glycoprotein found in the sera of patients diagnosed with gastrointestinal and other malignancies. TAG-72 was detected in the serum of a significant percentage of patients whose CEA levels were negative which underscores the possibility of exploiting the complementarity of the two tumor markers in the diagnosis of gastrointestinal (G.I.) carcinoma. Moreover, the measurement of TAG-72 may also be clinically useful in discriminating malignant from beningn effusions. Serum TAG-72 and CEA levels were evaluated longitudinally in a series of patients following resecton of primary G.I. carcinomas. A consistent relationship between efficacy of the surgery and serum TAG-72 clearance was observed, and TAG-72 alone or in combination with CEA accurately predicted recurrence of malignant disease in > 90% of the patients. The results indicate that TAG-72 is a new human serum tumor marker which, measured alone or in combination with other well established markers, may improve the diagnosis and/or clinical management of malignant disease.

Original languageEnglish
Pages (from-to)1389-1394
Number of pages6
JournalAnticancer Research
Volume11
Issue number4
Publication statusPublished - 1991

Fingerprint

Tumor Biomarkers
Serum
Carcinoma
Disease Management
tumor-associated antigen 72
Glycoproteins
Biomarkers
Molecular Weight
Recurrence
Neoplasms

Keywords

  • Body fluids
  • Carcinoembryonic antigen
  • Colorectal cancer
  • Radioimmunoassay
  • Stomach cancer
  • Tumor-associated glycoprotein-72

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Guadagni, F., Roselli, M., Ferroni, P., Amato, T., Colcher, D., Greiner, J. W., & Schlom, J. (1991). Clinical evaluation of the new tumor marker TAG-72. Anticancer Research, 11(4), 1389-1394.

Clinical evaluation of the new tumor marker TAG-72. / Guadagni, F.; Roselli, M.; Ferroni, P.; Amato, T.; Colcher, D.; Greiner, J. W.; Schlom, J.

In: Anticancer Research, Vol. 11, No. 4, 1991, p. 1389-1394.

Research output: Contribution to journalArticle

Guadagni, F, Roselli, M, Ferroni, P, Amato, T, Colcher, D, Greiner, JW & Schlom, J 1991, 'Clinical evaluation of the new tumor marker TAG-72', Anticancer Research, vol. 11, no. 4, pp. 1389-1394.
Guadagni F, Roselli M, Ferroni P, Amato T, Colcher D, Greiner JW et al. Clinical evaluation of the new tumor marker TAG-72. Anticancer Research. 1991;11(4):1389-1394.
Guadagni, F. ; Roselli, M. ; Ferroni, P. ; Amato, T. ; Colcher, D. ; Greiner, J. W. ; Schlom, J. / Clinical evaluation of the new tumor marker TAG-72. In: Anticancer Research. 1991 ; Vol. 11, No. 4. pp. 1389-1394.
@article{58fd2381d3e3489781a83cd60d2a6883,
title = "Clinical evaluation of the new tumor marker TAG-72",
abstract = "Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight glycoprotein found in the sera of patients diagnosed with gastrointestinal and other malignancies. TAG-72 was detected in the serum of a significant percentage of patients whose CEA levels were negative which underscores the possibility of exploiting the complementarity of the two tumor markers in the diagnosis of gastrointestinal (G.I.) carcinoma. Moreover, the measurement of TAG-72 may also be clinically useful in discriminating malignant from beningn effusions. Serum TAG-72 and CEA levels were evaluated longitudinally in a series of patients following resecton of primary G.I. carcinomas. A consistent relationship between efficacy of the surgery and serum TAG-72 clearance was observed, and TAG-72 alone or in combination with CEA accurately predicted recurrence of malignant disease in > 90{\%} of the patients. The results indicate that TAG-72 is a new human serum tumor marker which, measured alone or in combination with other well established markers, may improve the diagnosis and/or clinical management of malignant disease.",
keywords = "Body fluids, Carcinoembryonic antigen, Colorectal cancer, Radioimmunoassay, Stomach cancer, Tumor-associated glycoprotein-72",
author = "F. Guadagni and M. Roselli and P. Ferroni and T. Amato and D. Colcher and Greiner, {J. W.} and J. Schlom",
year = "1991",
language = "English",
volume = "11",
pages = "1389--1394",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Clinical evaluation of the new tumor marker TAG-72

AU - Guadagni, F.

AU - Roselli, M.

AU - Ferroni, P.

AU - Amato, T.

AU - Colcher, D.

AU - Greiner, J. W.

AU - Schlom, J.

PY - 1991

Y1 - 1991

N2 - Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight glycoprotein found in the sera of patients diagnosed with gastrointestinal and other malignancies. TAG-72 was detected in the serum of a significant percentage of patients whose CEA levels were negative which underscores the possibility of exploiting the complementarity of the two tumor markers in the diagnosis of gastrointestinal (G.I.) carcinoma. Moreover, the measurement of TAG-72 may also be clinically useful in discriminating malignant from beningn effusions. Serum TAG-72 and CEA levels were evaluated longitudinally in a series of patients following resecton of primary G.I. carcinomas. A consistent relationship between efficacy of the surgery and serum TAG-72 clearance was observed, and TAG-72 alone or in combination with CEA accurately predicted recurrence of malignant disease in > 90% of the patients. The results indicate that TAG-72 is a new human serum tumor marker which, measured alone or in combination with other well established markers, may improve the diagnosis and/or clinical management of malignant disease.

AB - Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight glycoprotein found in the sera of patients diagnosed with gastrointestinal and other malignancies. TAG-72 was detected in the serum of a significant percentage of patients whose CEA levels were negative which underscores the possibility of exploiting the complementarity of the two tumor markers in the diagnosis of gastrointestinal (G.I.) carcinoma. Moreover, the measurement of TAG-72 may also be clinically useful in discriminating malignant from beningn effusions. Serum TAG-72 and CEA levels were evaluated longitudinally in a series of patients following resecton of primary G.I. carcinomas. A consistent relationship between efficacy of the surgery and serum TAG-72 clearance was observed, and TAG-72 alone or in combination with CEA accurately predicted recurrence of malignant disease in > 90% of the patients. The results indicate that TAG-72 is a new human serum tumor marker which, measured alone or in combination with other well established markers, may improve the diagnosis and/or clinical management of malignant disease.

KW - Body fluids

KW - Carcinoembryonic antigen

KW - Colorectal cancer

KW - Radioimmunoassay

KW - Stomach cancer

KW - Tumor-associated glycoprotein-72

UR - http://www.scopus.com/inward/record.url?scp=0025719147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025719147&partnerID=8YFLogxK

M3 - Article

C2 - 1746895

AN - SCOPUS:0025719147

VL - 11

SP - 1389

EP - 1394

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -